Topics

Xtandi Demonstrates Significant Improvement in Overall Survival in Phase 3 Trial in Non-Metastatic Castration-Resistant Prostate Cancer

11:00 EST 12 Feb 2020 | Speciality Pharma Journal

TOKYO and NEW YORK, February 11, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men …

Original Article: Xtandi Demonstrates Significant Improvement in Overall Survival in Phase 3 Trial in Non-Metastatic Castration-Resistant Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Xtandi Demonstrates Significant Improvement in Overall Survival in Phase 3 Trial in Non-Metastatic Castration-Resistant Prostate Cancer"

Quick Search

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...